BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37293154)

  • 1.
    Santos M; Lanillos J; Caleiras E; Valdivia C; Roldan-Romero JM; Laínez N; Puente J; Beuselinck B; Oudard S; Zucman-Rossi J; Navarro P; Robledo M; Castellano D; de Velasco G; García-Donas J; Rodriguez-Antona C
    Am J Cancer Res; 2023; 13(5):2116-2125. PubMed ID: 37293154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With
    Liu Y; Li Y; Xu H; Zhou L; Yang X; Wang C
    Int J Surg Pathol; 2023 Dec; 31(8):1485-1494. PubMed ID: 36911986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of PBRM1 expression is associated with renal cell carcinoma progression.
    Pawłowski R; Mühl SM; Sulser T; Krek W; Moch H; Schraml P
    Int J Cancer; 2013 Jan; 132(2):E11-7. PubMed ID: 22949125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
    Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of PBRM1 in VHL disease-associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway.
    Gad S; Le Teuff G; Nguyen B; Verkarre V; Duchatelle V; Molinie V; Posseme K; Grandon B; Da Costa M; Job B; Meurice G; Droin N; Mejean A; Couve S; Renaud F; Gardie B; Teh BT; Richard S; Ferlicot S
    Oncol Lett; 2021 Dec; 22(6):835. PubMed ID: 34712359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
    Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
    Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Prediction Tool for Aggressive Tumors in Clinical T1 Stage Clear Cell Renal Cell Carcinoma Using Molecular Biomarkers.
    Park JS; Lee HJ; Cho NH; Kim J; Jang WS; Heo JE; Ham WS
    Comput Struct Biotechnol J; 2019; 17():371-377. PubMed ID: 30962867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J
    Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
    Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
    Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
    Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
    Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing.
    Lin PH; Huang CY; Yu KJ; Kan HC; Liu CY; Chuang CK; Lu YC; Chang YH; Shao IH; Pang ST
    Oncol Lett; 2021 Feb; 21(2):169. PubMed ID: 33456545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
    Rosellini M; Mollica V; Marchetti A; Coluccelli S; Giunchi F; Tassinari E; Ricci C; Fiorentino M; Tallini G; De Biase D; Massari F
    Pathol Res Pract; 2024 Feb; 254():155142. PubMed ID: 38277752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.
    Karlo CA; Di Paolo PL; Chaim J; Hakimi AA; Ostrovnaya I; Russo P; Hricak H; Motzer R; Hsieh JJ; Akin O
    Radiology; 2014 Feb; 270(2):464-71. PubMed ID: 24029645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and Predictive Value of
    Carril-Ajuria L; Santos M; Roldán-Romero JM; Rodriguez-Antona C; de Velasco G
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.
    Verbiest A; Lambrechts D; Van Brussel T; Couchy G; Wozniak A; Méjean A; Lerut E; Oudard S; Verkarre V; Job S; de Reynies A; Machiels JP; Patard JJ; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2018 Aug; 16(4):266-273. PubMed ID: 29503246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency of the X-inactivation escaping gene
    Zheng Q; Li P; Zhou X; Qiang Y; Fan J; Lin Y; Chen Y; Guo J; Wang F; Xue H; Xiong J; Li F
    Theranostics; 2021; 11(18):8674-8691. PubMed ID: 34522206
    [No Abstract]   [Full Text] [Related]  

  • 18. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
    Hagiwara M; Fushimi A; Matsumoto K; Oya M
    Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
    Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
    Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients.
    Liu T; Xia Q; Zhang H; Wang Z; Yang W; Gu X; Hou T; Chen Y; Pei X; Zhu G; He D; Li L; Xu S
    Aging (Albany NY); 2020 Nov; 12(21):21809-21836. PubMed ID: 33177244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.